Search clinical trials for: placebo atazanavir

Total 53631 results

Radboud University Medical Center
Dutch Diabetes Research Foundation

Completed

Effects of Atazanavir Treatment on Type 2 Diabetes Mellitus Related Endothelial Dysfunction (DM2ATV)

Type 2 Diabetes Mellitus Related Endothelial Dysfunction

Netherlands
Hospital do Coracao

Completed

Antiviral Agents Against COVID-19 Infection (REVOLUTIOn)

COVID-19

Brazil
University of Texas Southwestern Medical Center

Completed

Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo

Mild Gestational Diabetes

United States
Bristol-Myers Squibb

Completed

Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects

HIV

United States
Washington University School of Medicine
University of Maryland; United States Department of Defense

Completed

Glyburide Healthy Volunteer Study

Healthy Volunteers

United States
Asan Medical Center
Bristol-Myers Squibb

Unknown

Two Clinical Trials to Evaluate Pharmacokinetics of Unboosted and Boosted Atazanavir Used Alone or Co-administered With Tenofovir DF in Healthy Korean and Caucasian Male Volunteers

Atazanavir

Korea, Republic of
Brigham and Women's Hospital

Completed

Atazanavir and Endothelial Function in Older HIV Patients

HIV

United States
Bristol-Myers Squibb

Completed

Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone

HIV Infections

United States
Bristol-Myers Squibb

Completed

A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy

HIV Infections

United States
Bristol-Myers Squibb
Merck Sharp & Dohme LLC

Completed

DDI HV (ATV - Merck)

HIV Infections

United States
Bristol-Myers Squibb

Completed

Drug Interaction Study With Proton Pump Inhibitor

HIV Infections

United States
Giovanni Di Perri
University of Turin, Italy; University of Milan

Terminated

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir (RALBAT)

HIV Infection | Osteopenia

Italy
Bristol-Myers Squibb

Completed

Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat (Atazanavir)

Human Immunodeficiency Virus Type 1 (HIV-1)

United States
University of British Columbia

Completed

Switch to Unboosted Atazanavir With Tenofovir Study (SUAT)

HIV Infection

Canada
Bristol-Myers Squibb

Completed

Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study) (INDUMA)

HIV Infections

Spain, Italy, United Kingdom, France, Russian Federation, Ireland, Germany, Latvia, Estonia, Portugal
Brigham and Women's Hospital
National Institutes of Health (NIH)

Completed

A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
Bristol-Myers Squibb

Completed

A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time

Healthy Participants

United States
Indiana University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors

Endothelial Dysfunction

United States
Bristol-Myers Squibb

Terminated

A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome

HIV Infections

France
The University of Texas Health Science Center,...

Withdrawn

Failure Rate of GLyburide And Metformin Among Gestational Diabetics (GLAM)

Gestational Diabetes Mellitus, Class A2
Bristol-Myers Squibb

No longer available

Atazanavir for HIV Infected Individuals: An Early Access Program

HIV Infections

United States, Puerto Rico
The HIV Netherlands Australia Thailand Research...
Bristol-Myers Squibb

Completed

Pharmacokinetic Study of 2 Doses of ATV/r OD + 2 NRTIs in Thai HIV-1 Infected Patients

HIV Infections

Thailand
Foundation for Cardiovascular Research, Zurich
Bristol-Myers Squibb

Completed

Effect of Atazanavir on Endothelial Function in HIV-Infected Patients (ENDOPACT)

HIV Infections | Dyslipidemia

Switzerland
University of Liverpool
University of Cape Town; Desmond Tutu HIV Foundation; Infectious Diseases Institute... and other collaborators

Completed

Pharmacokinetics of Atazanavir in Special Populations (VirTUAL WP5)

HIV/AIDS | Tuberculosis

Uganda, South Africa
Bristol-Myers Squibb

Completed

PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV) (PRINCE1)

HIV Infections

Thailand, Chile, Peru, Brazil, Mexico, South Africa
Bristol-Myers Squibb

Completed

Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients

HIV Infections

United States
University of Roma La Sapienza

Unknown

ATAGLU: Study of Glucose Metabolism in HIV Positive Patients That Switch From Another Protease Inhibitor to Atazanavir (ATAGLU)

HIV

Italy
Stanford University
Bristol-Myers Squibb

Completed

Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With Hyperlipidemia

HIV Infections | Hyperlipidemia

United States
Bristol-Myers Squibb

Completed

A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions

Healthy Participants

United States
Bristol-Myers Squibb

Terminated

A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor

HIV Infections

United States, Mexico, Canada, Puerto Rico, Thailand
Phoenix Children's Hospital
Bristol-Myers Squibb

Completed

Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens

HIV Infections | Pediatric HIV

United States
Bristol-Myers Squibb

Completed

Atazanavir Twice Daily

HIV Infections | Protease Inhibitor

United States
University of Colorado, Denver
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Genetics and HIV-1 Protease Inhibitors

HIV

United States
University of California, San Francisco

Completed

Effects of Gastric pH on the Pharmacokinetics of Atazanavir

Healthy

United States
The HIV Netherlands Australia Thailand Research...
amfAR, The Foundation for AIDS Research; National Health Security Office, Thailand and other collaborators

Completed

Atazavanir/Ritonavir-based HAART in Children

HIV

Thailand
Northwestern University
Bristol-Myers Squibb

Completed

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study (SABAR)

HIV Infection | Hyperlipidemia

United States, Argentina, Italy
Fundacion SEIMC-GESIDA
Bristol-Myers Squibb

Completed

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy (SALT)

HIV Infection

Spain
Bristol-Myers Squibb

Completed

Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients

HIV Infections

United States, United Kingdom
Community Research Initiative of New England
Bristol-Myers Squibb; Merck Sharp & Dohme LLC

Completed

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated. (BATAR)

HIV

United States
Institut de Médecine et d'Epidémiologie Appliquée...

Completed

Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts (DATA)

HIV-1 Infection | Immunosuppression-related Infectious Disease

France
Radboud University Medical Center

Completed

The Effects of Atazanavir-induced Hyperbilirubinemia During Human Endotoxemia

Sepsis | Inflammation | Endotoxemia | Multi Organ Dysfunction Syndrome

Netherlands
NeuroActiva, Inc.
Biomed Industries, Inc.

Recruiting

NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection (NATADEX)

Coronavirus Infection | Severe Acute Respiratory Syndrome Coronavirus 2 | Severe Acute Respiratory Infection

United States
Catholic University of the Sacred Heart

Completed

Atazanavir/r + Lamivudine Dual Therapy (ATLAS)

Human Immunodeficiency Virus

Italy
Bristol-Myers Squibb

Completed

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

HIV

Argentina, France, Taiwan, Thailand, United States, Chile, Spain, Dominican Republic, Guatemala, Peru, Puerto Rico, Singapore, Russian Federation, Italy, Mexico, Colombia, South Africa, Brazil, Hungary, Malaysia, Portugal, Canada, I... and more
Kenneth H. Mayer, MD
Bristol-Myers Squibb; Gilead Sciences; Abbott

Terminated

Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV (BMS PEP)

HIV

United States
David Garcia Cinca
Fundacion Clinic per a la Recerca Biomédica

Unknown

Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia (Osteosimply014)

Human Immunodeficiency Virus

Spain
Peter J. Ruane, M.D., Inc.

Unknown

Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment

HIV Infections

United States
Takeda

Completed

Safety Study of Pioglitazone Compared To Glyburide on Liver Function

Diabetes Mellitus | Liver
International Medical Center of Japan
Ministry of Health, Labour and Welfare, Japan

Completed

Comparison of Epzicom and Truvada for the Initial Once Daily HIV Treatment

HIV Infections

Japan
St. James's Hospital, Ireland

Unknown

Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users

HIV Infections | Hepatitis C

Ireland

Search clinical trials for: placebo atazanavir

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations